We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications (CSSC-004)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04373460
Recruitment Status : Active, not recruiting
First Posted : May 4, 2020
Last Update Posted : June 7, 2022
Sponsor:
Collaborators:
State of Maryland
Bloomberg Foundation
United States Department of Defense
National Institute of Allergy and Infectious Diseases (NIAID)
National Center for Advancing Translational Sciences (NCATS)
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.

Condition or disease Intervention/treatment Phase
SARS-CoV 2 Biological: SARS-CoV-2 convalescent plasma Biological: Plasma from a volunteer donor Phase 2

Detailed Description:
The purpose of this randomized, double-blind, controlled, phase 2 trial is to evaluate the efficacy of treatment with HCIP in reducing hospitalization and death prior to hospitalization among outpatient adults who have RNA detection test-confirmed COVID-19 AND have developed any symptoms of COVID-19 including but not limited to fever, cough, or other COVID associated symptoms like anosmia. Ambulatory/outpatient adults subjects 18 years of age or older, regardless of risk factors for severe illness may participate. A total of approximately 1344 eligible subjects stratified with a target goal (but not binding) of 50:50 in the <65 vs ≥ 65 age range will be randomized in a 1:1 ratio to receive either HCIP or control plasma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1225 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A total of approximately 1344 eligible subjects stratified with a target goal (but not binding) of 50:50 in the <65 vs ≥ 65 age range will be randomized in a 1:1 ratio to receive either HCIP or control plasma.
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19
Actual Study Start Date : June 3, 2020
Actual Primary Completion Date : January 14, 2022
Estimated Study Completion Date : September 14, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: SARS-CoV-2 convalescent plasma
SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
Biological: SARS-CoV-2 convalescent plasma
SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
Other Name: Human coronavirus immune plasma (HCIP)

Active Comparator: Standard Control plasma
Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
Biological: Plasma from a volunteer donor
Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.




Primary Outcome Measures :
  1. Cumulative incidence of hospitalization or death prior to hospitalization [ Time Frame: Up to day 28 ]
    Cumulative incidence measured as the proportion of subjects who were hospitalized or who died prior to hospitalization

  2. Cumulative incidence of treatment-related serious adverse events [ Time Frame: Up to day 28 ]
    Cumulative incidence of treatment-related serious adverse events categorized separately as either severe infusion reactions or Acute Respiratory Distress Syndrome (ARDS) during the study period.

  3. Cumulative incidence of treatment-related grade 3 or higher adverse events [ Time Frame: Up to day 90 ]
    Cumulative incidence measured as the proportion of subjects experiencing a Grade 3 or higher.


Secondary Outcome Measures :
  1. Change in serum SARS-CoV-2 antibody titers [ Time Frame: Days 0, 14, 28 and 90 ]
    Analysis of serum SARS-CoV-2 antibody titers will also primarily be descriptive, comparing the geometric mean titers at day 0, 14, 28 and 90 between the randomized arms and calculating the shift or change in the titer distribution.

  2. Time to SARS-CoV-2 Polymerase Chain Reaction (PCR) negativity [ Time Frame: Day 0, 14 and 28 ]
    Compare the rates and duration of SARS-CoV-2 RNA positivity by Real-Time (RT)-PCR of nasopharyngeal or oropharyngeal fluid between active and control groups at days 0, 14 and 28. PCR results take up to 6 months to process and be available to the study team for data analysis.


Other Outcome Measures:
  1. Change in level of SARS-CoV-2 RNA [ Time Frame: Day 0, 14 and 28 ]
    Compare the levels of SARS-CoV-2 RNA between active and control groups at days 0, 14 and 28. RNA results take up to 6 months to process and be available to the study team for data analysis.

  2. Change in oxygen saturation levels [ Time Frame: Day 0 to Day 28 (where available) ]
    Comparison of participant self-assessed blood oxygen saturation levels (in percentage oxygen) between treatment arms using pulse oximetry from Day 0 to Day 28.

  3. Rate of participant-reported secondary infection of housemates [ Time Frame: Up to day 90 ]
    Secondary infection will be assessed by measuring the number of individuals that live in the same house as the active arm who became sick by the end of follow-up period.

  4. Time to ICU admission, invasive mechanical ventilation or death in hospital [ Time Frame: Up to day 90 ]
    Disease severity measured by time (in days) to admission to the ICU or , invasive mechanical ventilation or time to death.

  5. Time to resolution of COVID-19 symptoms [ Time Frame: Up to day 90 ]
    Time (in days) to resolution of COVID-19 symptoms will be based on temperature logs and symptom score sheets.

  6. Impact of convalescent plasma on outcome as assessed by change in hospitalization rate [ Time Frame: Day 0 to Day 90 ]
    Assess change in hospitalization rate as measured by number of hospitalizations stratified by age groups <65 and >=65

  7. Impact of donor antibody titers on hospitalization rate of convalescent plasma recipients [ Time Frame: Day 0 to Day 90 ]
    Impact of donor antibody titers (high/low) will be assessed by hospitalization rate as measured by number of hospitalizations.

  8. Impact of donor antibody titers on antibody levels of convalescent plasma recipients [ Time Frame: Day 0 to Day 90 ]
    Impact of donor antibody titers (high/low) will be assessed by antibody levels

  9. Impact of donor antibody titers on viral positivity rates of convalescent plasma recipients [ Time Frame: Day 0 to Day 90 ]
    Impact of donor antibody titers (high/low) will be assessed by viral positivity rates (number of SARS-CoV-2 positive cases per total cases)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ≥ 18 years of age
  • Competent and capable to provide informed consent
  • • Positive molecular test for presence of SARS-CoV-2 in fluid collected by saliva for antigen, oropharyngeal or nasopharyngeal swab
  • Experiencing any symptoms of COVID-19 including but not limited to fever(T> 100.5º F), cough, or other COVID associated symptoms like anosmia
  • ≤ 8 days since the first symptoms of COVID-19
  • ≤ 8 days since first positive SARS-CoV-2 RNA test
  • Able and willing to comply with protocol requirements listed in the informed consent

Exclusion Criteria:

  • Hospitalized or expected to be hospitalized within 24 hours of enrollment
  • Psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance
  • History of prior reactions to transfusion blood products
  • Inability to complete therapy with the study product within 24 hours after enrollment
  • Receiving any treatment drug for COVID-19 within 14 days prior to screening evaluation (monoclonal antibodies, compassionate use or study trial related). Steroid treatment at any time does not affect study eligibility

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04373460


Locations
Show Show 25 study locations
Sponsors and Collaborators
Johns Hopkins University
State of Maryland
Bloomberg Foundation
United States Department of Defense
National Institute of Allergy and Infectious Diseases (NIAID)
National Center for Advancing Translational Sciences (NCATS)
Investigators
Layout table for investigator information
Principal Investigator: David J Sullivan, MD The Johns Hopkins University
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT04373460    
Other Study ID Numbers: IRB00247590
R01AI152078 ( U.S. NIH Grant/Contract )
W911QY2090012 ( Other Grant/Funding Number: Department of Defense )
First Posted: May 4, 2020    Key Record Dates
Last Update Posted: June 7, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymized individual participant data (IPD) collected in this study, including data dictionaries, will be made available to other researchers after the end of the study.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: After publication of initial study manuscript
Access Criteria: Public

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Johns Hopkins University:
COVID-19